In the STEP 1 extension, people who stopped semaglutide regained 11.6 percentage points of body weight over 52 weeks, ending with an average net loss of 5.6% from baseline while lifestyle support continued (STEP 1 extension data)
In cases of discrepancy between structured prescription fields and chart documentation, clinician-documented diagnoses were considered the primary source for classification of discontinuation cause
As with any medication, its important to use Wegovy under the supervision and guidance of a healthcare professional
Collaboration with healthcare providers and the incorporation of healthy habits can enhance the advantages of semaglutide injections in attaining weight loss goals and enhancing overall health and well-being
At a Glance What It Is & Composition Semaglutide is a single-molecule GLP-1 receptor agonist an analogue of human GLP-1 engineered for a long half-life (about a week), which is what allows once-weekly rather than daily dosing

When to Seek Medical Advice Patients should contact their healthcare provider if they experience: Severe, persistent fatigue not improving with adequate nutrition and rest Inability to maintain adequate protein or caloric intake due to gastrointestinal side effects Signs of hypoglycemia (especially in patients taking insulin or sulfonylureas) Symptoms suggesting thyroid dysfunction Severe abdominal pain, especially if radiating to the back (possible pancreatitis) Right upper quadrant pain, fever, or jaundice (possible gallbladder disease) Persistent vomiting or signs of dehydration Concerns about excessive weight loss that should be evaluated individually These situations warrant clinical evaluation to distinguish normal treatment effects from complications requiring intervention